Cellsway

Cellsway

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Cellsway is a private, pre-revenue diagnostics company pioneering a microfluidic CTC liquid biopsy platform. Its integrated system combines a patented size-based enrichment device with proprietary downstream immunofluorescence assay panels to profile cancer biomarkers from blood. The company is currently conducting a 300-patient clinical study to optimize its workflow and has initiated commercial partnerships, such as with Omega Genetik in Turkey, signaling a transition towards market entry and validation.

Oncology

Technology Platform

Integrated microfluidic liquid biopsy platform for the size-based enrichment, identification, and immunofluorescence-based characterization of Circulating Tumor Cells (CTCs) from blood.

Opportunities

The growing demand for minimally invasive, dynamic cancer monitoring presents a large market.
Cellsway's fully automated, distributed lab model could capture value from service laboratories seeking in-house liquid biopsy capabilities.
Further assay development for additional cancer types and biomarkers could expand its market reach.

Risk Factors

The platform's clinical utility must be proven against established standards and competing technologies like cfDNA tests.
Navigating complex regulatory pathways and securing reimbursement are significant hurdles.
The company faces intense competition in the crowded liquid biopsy market.

Competitive Landscape

Cellsway competes in the CTC isolation segment against companies like Menarini Silicon Biosystems (CellSearch) and Fluxion Biosciences, and more broadly against the dominant cfDNA liquid biopsy players (e.g., Guardant Health, Freenome). Its differentiation lies in a fully automated, rapid workflow designed for distributed service labs rather than central facilities.